Matrigel Dome Assay And Drug Screening Of Colorectal Cancer Organoids

By Prathyushakrishna Macha, Oksana Sirenko, Jay Hoying, and Angeline Lim

This content is brought to you by Molecular Devices, a Danaher Operating Company.

We chose colorectal cancer (CRC) organoids as our model system for investigating drug responses to utilize established anti-cancer compounds to evaluate the effectiveness of robotics-based assay development. To facilitate this, we employed the BioAssemblyBot® 400 (BAB400), which was instrumental in automating the CRC dome assays. This automation ensured the consistent and uniform distribution of patient-derived colorectal cancer organoids. The organoids were seeded and subsequently maintained under controlled conditions for a duration of six days. During this period, they were subjected to various treatments with the selected anti-cancer compounds.

Explore how drug responses were assessed with an image-based end-point assay, which provided valuable insights into the efficacy of the treatments administered.